drugset
drugset / Trial / NCT06798727

Evaluation Safety and Explore Efficacy Long-term Follow-up Study on Subjects Receiving SMUP-IA-01 or Active Control

NCT06798727 ↗

Phase 2 Active not recruiting 84 enrolled Medipost Co Ltd.
Non-randomizedParallel-groupDouble-blindTreatment

Summary

This is a follow-up study to investigate the long-term safety and explore efficacy of SMUP-IA-01, for the treatment of Knee Osteoarthritis. Subjects who participated in and completed the initial stage of the Phase II trial (NCT05182034) will be followed-up until 60 months.

Timeline

Start
2023-03-20
Primary completion
2027-03-20
Completion
2027-11-30

Drugs

EvaluationDrugModalityDoseRoute
Subject SMUP-IA-01 Cell therapy 4e+06 cells Other
Subject SMUP-IA-01 Cell therapy 1e+07 cells Other
Comparator Sodium Hyaluronate Other / unclassified 20 mg Other

Indications

osteoarthritis, knee